Eli Lilly and Company and Merck announced an immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly’s cyclin-dependent kinase 4 and 6 inhibitor, and Merck’s Keytruda (pembrolizumab) in a phase I study across multiple tumor types. Based on the trial’s results, the collaboration has the potential to progress to phase II trials in patients who have...
“I don’t think any good cancer center director would be worth their weight in salt if they weren’t worried about something at night,” said Mark Evers, director of University of Kentucky Markey Cancer Center.
